Sung Ouk Nam1, Fusanori Yotsumoto2, Kohei Miyata1, Yuki Suzaki3, Hiroshi Yagi4, Takashi Odawara5, Sadao Manabe5, Toyokazu Ishikawa5, Masahide Kuroki6, Eisuke Mekada7, Shingo Miyamoto8. 1. Department of Obstetrics and Gynecology, Fukuoka University, Fukuoka, Japan Department of Biochemistry, Faculty of Medicine, Fukuoka University, Fukuoka, Japan Department of Central Research Institute for Advanced Molecular Medicine, Fukuoka University, Fukuoka, Japan. 2. Department of Biochemistry, Faculty of Medicine, Fukuoka University, Fukuoka, Japan Department of Central Research Institute for Advanced Molecular Medicine, Fukuoka University, Fukuoka, Japan. 3. Medical Center for Translational Research, Osaka University Hospital, Osaka, Japan. 4. Department of Obstetrics and Gynecology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan. 5. Kanonji Institute, Research Foundation for Microbial Diseases of Osaka University, Kagawa, Japan. 6. Department of Biochemistry, Faculty of Medicine, Fukuoka University, Fukuoka, Japan. 7. Department of Cell Biology, Research Institute for Microbial Diseases, Osaka University, Osaka, Japan. 8. Department of Obstetrics and Gynecology, Fukuoka University, Fukuoka, Japan Department of Central Research Institute for Advanced Molecular Medicine, Fukuoka University, Fukuoka, Japan smiya@cis.fukuoka-u.ac.jp.
Abstract
BACKGROUND/AIM: Heparin-binding epidermal growth factor-like growth factor (HB-EGF), a member of the epidermal growth factor family, is a target for ovarian cancer therapy. The present study investigated the administration schedule of BK-UM, an anticancer agent targeting HB-EGF. MATERIALS AND METHODS: The ovarian cancer cell line, RMG-I, was injected subcutaneously into five-week-old female nude mice. The BK-UM was administered intraperitoneally, using three administration schedules with different doses. The tumor volume was calculated every week. Statistical significance was assessed using the Mann-Whitney U-test. RESULTS: At doses >0.1 mg/kg, BK-UM displayed significant antitumor effects, although the antitumor effects and body weights of mice did not significantly differ by dose or by three different administration schedules. At a dose <0.1 mg/kg, however, BK-UM had little inhibitory effect on tumor growth. CONCLUSION: Daily administration of BK-UM, which has a potentially dose-dependent antitumor effect, may be the optimal schedule for clinical application. Copyright
BACKGROUND/AIM: Heparin-binding epidermal growth factor-like growth factor (HB-EGF), a member of the epidermal growth factor family, is a target for ovarian cancer therapy. The present study investigated the administration schedule of BK-UM, an anticancer agent targeting HB-EGF. MATERIALS AND METHODS: The ovarian cancer cell line, RMG-I, was injected subcutaneously into five-week-old female nude mice. The BK-UM was administered intraperitoneally, using three administration schedules with different doses. The tumor volume was calculated every week. Statistical significance was assessed using the Mann-Whitney U-test. RESULTS: At doses >0.1 mg/kg, BK-UM displayed significant antitumor effects, although the antitumor effects and body weights of mice did not significantly differ by dose or by three different administration schedules. At a dose <0.1 mg/kg, however, BK-UM had little inhibitory effect on tumor growth. CONCLUSION: Daily administration of BK-UM, which has a potentially dose-dependent antitumor effect, may be the optimal schedule for clinical application. Copyright